Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a biopharmaceutical company based in China, has entered into a licensing agreement with Cristália Produtos Químicos Farmacêuticos LTDA, a Brazil-headquartered pharmaceutical company. Cristália will take on the responsibility for the regulatory submission and commercialization of Mabwell’s biosimilars MAILISHU (9MW0311) and MAIWEIJIAN (9MW0321) in Brazil, which are biosimilars of denosumab.
9MW0321 is being developed as a biosimilar to Xgeva (denosumab), while 9MW0311 is intended as a biosimilar to Prolia (denosumab). Denosumab, originally developed by Amgen, is a RANKL inhibitor used for various bone-related conditions and is currently marketed in China by BeiGene. Mabwell’s MAILISHU received approval from the China National Medical Products Administration (NMPA) in March 2023, and MAIWEIJIAN followed suit in March 2024.
As part of its international expansion strategy, Mabwell has established partnerships with several overseas companies to facilitate the local commercialization of its products. These collaborations include agreements with Searle in Pakistan, Legrand in Colombia and Ecuador, Innobic in Asia, and other regional partners.- Fineline.com
